GlassScriptPhysician profile
Kristin Downs
NPI 1669936506
$2,073.21
in general payments reported to CMS, 2019-2025
21 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $612 · 2024: $573 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.82 | 2022-2025 | |
| Boston Scientific Corporation | $324.58 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Collegium Pharmaceutical, INC. | $304.72 | 2022-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.80 | 2022-2025 | Relistor |
| Virtus Pharmaceuticals LLC | $115.13 | 2024 | Levorphanol Tartrate |
| Nevro Corp. | $82.54 | 2022-2024 | Senza |
| Amgen INC. | $69.59 | 2022 | |
| Relievant Medsystems, INC. | $67.90 | 2022-2023 | Intracept |
| Teva Pharmaceuticals USA, INC. | $56.24 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $47.35 | 2022-2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $44.11 | 2023-2024 | Horizant, Horizant |
| Vertex Pharmaceuticals Incorporated | $41.29 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $31.35 | 2023 | Zilretta |
| Siemens Medical Solutions USA, INC. | $26.94 | 2024 | Cios Select |
| Saluda Medical Americas, INC. | $22.17 | 2024 | Evoke |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $19.68 | 2025 | Hymovis, Triluron |
| Biohaven Pharmaceutical Holding Company LTD. | $19.34 | 2022 | |
| Si-Bone, INC. | $17.87 | 2023 | |
| Horizon Therapeutics Plc | $15.37 | 2022 | |
| Nalu Medical, INC. | $15.07 | 2025 | Nalu Neurostimulation System |
| Pfizer INC. | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.